PharmaDiagnostics launches SoPRano assay kit for in-house assay
15 Sept 2010
Brussels based PharmaDiagnostics NV has launched the SoPRano
CA1 assay kit. The new kit allows users to couple their own proteins to
SoPRano gold nanoparticles and build and run their own assays.
This was previously available only as a service provided by
PharmaDiagnostics, and the new kit will now greatly expand the
accessibility and utility of the technology to customers.
SoPRano technology is based on a variant of the well-established
surface plasmon resonance (SPR) phenomenon, and for the first time
makes label-free screening available in high throughput on a
Label-free screening is an area of great interest and growth in
pharmaceutical research. To date, the expanding SPR segment of this
market has been dominated by providers of expensive specialist
instrumentation that is unable, due to technical constraints, to
provide the throughput required for routine screening.
With the launch of the first in a new family of kits,
PharmaDiagnostics is now able to deliver on the promise of
label-free SPR screening by enabling researchers to develop and run
their own high-quality, cost-effective assays without the need for
expensive capital equipment.
The kits enable users to develop assays for a range of
applications, including fragment screening, focused high throughput
screening (HTS), antibody discovery, and hit confirmation. The
company also already offers SoPRano kits for a range of ADME and
physicochemical properties, including plasma protein binding, pKa
and redox potential.
PharmaDiagnostics’ SoPRano label-free platform is the first
SPR-based system to utilize standard plate-readers, and simple assay
protocols. This increases for researchers, lowers barrier to
adoption and also offers excellent scalability, thus lowering costs,
as it is not necessary to increase instrument expenditure to
“The new SoPRano assay kit is another illustration of
PharmaDiagnostics’ commitment towards providing broader access to
label-free screening technology,” said Dr David Ricketts, CEO at
PharmaDiagnostics. “We have seen that the market is seeking flexible
access to label-free screening technology, which we now offer both
as a service in PharmaDiagnostics’ laboratories, as well as through
the SoPRano kits which enable customers to develop and run their own